8 active warrant series covering 37,167,631 shares (~27.5% potential dilution); nearest expiry 2027-01-13.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| warrant | $0.12 | Jan 13, 2027 105d | 2.5M | OTM | 1.9% | C$304K | Auto |
| warrant | $0.12 | Feb 27, 2027 150d | 4.6M | OTM | 3.4% | C$552K | Auto |
| warrant | $0.14 | Apr 25, 2027 207d | 9.9M | OTM | 7.3% | C$1.3M | Auto |
| warrant | $0.08 | Oct 6, 2028 737d | 8.8M | OTM | 6.5% | C$700K | Filed |
| warrant | $0.08 | Oct 21, 2028 752d | 1.3M | OTM | 1.0% | C$105K | Auto |
| warrant | $0.06 | Apr 8, 2029 921d | 5.1M | OTM | 3.7% | C$304K | Auto |
| finder | $0.06 | Aug 11, 2029 1046d | 192K | OTM | 0.1% | C$12K | Auto |
| warrant | $0.06 | Aug 11, 2029 1046d | 4.9M | OTM | 3.6% | C$291K | Auto |
Basis: Current shares & price vs as-filed warrant terms.
6 option grants covering 6,625,000 shares (~4.9% potential dilution). Counted apart from the warrants above.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| option | $0.10 | Jan 30, 2029 853d | 400K | OTM | 0.3% | C$40K | Auto |
| option | $0.10 | Jun 24, 2029 998d | 675K | OTM | 0.5% | C$68K | Auto |
| option | $0.05 | Mar 10, 2031 1622d | 200K | OTM | 0.1% | C$10K | Auto |
| option | $0.20 | Jun 30, 2032 2100d | 4.0M | OTM | 3.0% | C$810K | Auto |
| option | $0.10 | Jan 30, 2034 2679d | 350K | OTM | 0.3% | C$35K | Auto |
| option | $0.10 | Jun 24, 2034 2824d | 950K | OTM | 0.7% | C$95K | Auto |
135,359,168 shares outstanding, plus 37,167,631 from warrants and 6,625,000 from options — a fully diluted 179,151,799 shares, or ~32.4% above today's count if every one of them is exercised.
Price history with the company's supply walls overlaid — warrants (amber), employee and consultant options (pink), and free-trading unlock dates (violet). Each wall sits at the price the paper is struck at today, restated through any consolidation, and is measured in the SHARES it can issue rather than the number of certificates. Levels and dates are Pacific Time.
8 active warrant series covering 37,167,631 shares (~27.5% potential dilution); nearest expiry 2027-01-13.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| warrant | $0.12 | Jan 13, 2027 105d | 2.5M | OTM | 1.9% | C$304K | Auto |
| warrant | $0.12 | Feb 27, 2027 150d | 4.6M | OTM | 3.4% | C$552K | Auto |
| warrant | $0.14 | Apr 25, 2027 207d | 9.9M | OTM | 7.3% | C$1.3M | Auto |
| warrant | $0.08 | Oct 6, 2028 737d | 8.8M | OTM | 6.5% | C$700K | Filed |
| warrant | $0.08 | Oct 21, 2028 752d | 1.3M | OTM | 1.0% | C$105K | Auto |
| warrant | $0.06 | Apr 8, 2029 921d | 5.1M | OTM | 3.7% | C$304K | Auto |
| finder | $0.06 | Aug 11, 2029 1046d | 192K | OTM | 0.1% | C$12K | Auto |
| warrant | $0.06 | Aug 11, 2029 1046d | 4.9M | OTM | 3.6% | C$291K | Auto |
Basis: Current shares & price vs as-filed warrant terms.
6 option grants covering 6,625,000 shares (~4.9% potential dilution). Counted apart from the warrants above.
| Type | Status | Source | |||||
|---|---|---|---|---|---|---|---|
| option | $0.10 | Jan 30, 2029 853d | 400K | OTM | 0.3% | C$40K | Auto |
| option | $0.10 | Jun 24, 2029 998d | 675K | OTM | 0.5% | C$68K | Auto |
| option | $0.05 | Mar 10, 2031 1622d | 200K | OTM | 0.1% | C$10K | Auto |
| option | $0.20 | Jun 30, 2032 2100d | 4.0M | OTM | 3.0% | C$810K | Auto |
| option | $0.10 | Jan 30, 2034 2679d | 350K | OTM | 0.3% | C$35K | Auto |
| option | $0.10 | Jun 24, 2034 2824d | 950K | OTM | 0.7% | C$95K | Auto |
135,359,168 shares outstanding, plus 37,167,631 from warrants and 6,625,000 from options — a fully diluted 179,151,799 shares, or ~32.4% above today's count if every one of them is exercised.
Price history with the company's supply walls overlaid — warrants (amber), employee and consultant options (pink), and free-trading unlock dates (violet). Each wall sits at the price the paper is struck at today, restated through any consolidation, and is measured in the SHARES it can issue rather than the number of certificates. Levels and dates are Pacific Time.
An issuer that discloses only a plan total appears as one line at its weighted-average exercise price and weighted-average remaining life — the filing's own summary, not a per-grant schedule.
An issuer that discloses only a plan total appears as one line at its weighted-average exercise price and weighted-average remaining life — the filing's own summary, not a per-grant schedule.
